Physician profile
Keung Lee
NPI 1932186301
$11,757.90
in general payments reported to CMS, 2019-2025
61 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,154 · 2020: $4,010 · 2021: $1,029 · 2022: $1,356 · 2023: $1,468 · 2024: $1,018 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,006.76 |
| Education | $201.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,996.07 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $952.57 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $849.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $646.36 | 2021-2025 | |
| Pfizer INC. | $558.26 | 2019-2025 | |
| Lilly USA, LLC | $553.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Preventric Diagnostics, INC. | $410.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.72 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $288.58 | 2019-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $286.08 | 2019-2022 | |
| Amgen INC. | $274.80 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $264.80 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.19 | 2019-2023 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $201.64 | 2023 | |
| Astellas Pharma US INC | $191.24 | 2019-2024 | Veozah |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $178.91 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $172.55 | 2019-2021 | |
| Eisai INC. | $170.76 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.04 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $160.20 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $158.83 | 2020-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $129.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Orexo US, INC. | $124.28 | 2019-2024 | Zubsolv |
| Merck Sharp & Dohme LLC | $118.04 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Biohaven Pharmaceuticals, INC. | $89.24 | 2021 | |
| Biogen, INC. | $89.14 | 2019-2024 | Leqembi |
| Teva Pharmaceuticals USA, INC. | $73.23 | 2019-2022 | |
| Mylan Specialty L.P. | $72.18 | 2020-2024 | Yupelri |
| Shield Therapeutics INC | $63.96 | 2023-2024 | Accrufer |
| Medtronic, INC. | $61.75 | 2023-2024 | Intellis Adaptivestim |
| Dexcom, INC. | $60.92 | 2023-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $53.45 | 2022 | |
| Gilead Sciences, INC. | $52.18 | 2023-2025 | |
| Corium, LLC | $47.73 | 2023 | Adlarity |
| Viatris Specialty LLC | $42.07 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $41.95 | 2022-2023 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $40.63 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $40.17 | 2021 | |
| Avanir Pharmaceuticals, INC. | $39.34 | 2019 | |
| Axsome Therapeutics, INC. | $38.33 | 2023 | Auvelity |
| Lundbeck LLC | $38.03 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.13 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.77 | 2019 | |
| Shire North American Group INC | $32.33 | 2019 | |
| Philips North America LLC | $31.59 | 2020 | |
| Allergan, INC. | $31.11 | 2020 | |
| Tolmar, INC. | $30.79 | 2023-2024 | |
| Ironwood Pharmaceuticals, INC | $25.10 | 2019-2023 | Linzess |
| Baxter Healthcare | $20.48 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Neurocrine Biosciences, INC. | $20.39 | 2023 | Ingrezza |
| Mdd US Operations, LLC | $20.32 | 2020 | |
| Ironshore Pharmaceuticals INC. | $19.79 | 2024 | |
| Valeritas, INC. | $18.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.64 | 2025 | Voquezna |
| Indivior INC. | $15.53 | 2019 | |
| Abbott Laboratories | $14.23 | 2019 | |
| Uswm, LLC | $12.53 | 2022 | |
| Sumitomo Pharma America, INC. | $12.15 | 2023 | Gemtesa |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keung Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.